Atrial Fibrillation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Atrial fibrillation pipeline market research report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects.

Key Targets in the Atrial Fibrillation Pipeline Market

The key targets in the atrial fibrillation pipeline market are Potassium Channel, Sodium Channel, Calcium Channel, Beta 1 Adrenergic Receptor, Coagulation Factor X, Coagulation Factor XI, and Muscarinic Gated Atrial Potassium Channel. Potassium Channel has the highest number of pipeline products in the atrial fibrillation pipeline market.

Atrial Fibrillation Pipeline Market, by Targets

Atrial Fibrillation Pipeline Market, by Targets

For more target insights, download a free report sample

Key MoA in the Atrial Fibrillation Pipeline Market

The key MoA in the atrial fibrillation pipeline market are Potassium Channel Blocker, Sodium Channel Blocker, Calcium Channel Blocker, Beta 1 Adrenergic Receptor Antagonist, Coagulation Factor X Inhibitor, and Coagulation Factor XI Inhibitor. Potassium Channel Blocker has the highest number of pipeline products.

Atrial Fibrillation Pipeline Market, by MoA

Atrial Fibrillation Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Atrial Fibrillation Pipeline Market

The key RoA in the atrial fibrillation pipeline market are oral, intravenous, inhalational, intracardiac, intramuscular, nasal, parenteral, and subcutaneous. Oral has the highest number of pipeline products.

Atrial Fibrillation Pipeline Market, by RoA

Atrial Fibrillation Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Atrial Fibrillation Pipeline Market

The key molecule types in the atrial fibrillation pipeline market are small molecule, gene therapy, protein, monoclonal antibody. Small molecule has the highest number of pipeline products.

Atrial Fibrillation Pipeline Market, by Molecule Types

Atrial Fibrillation Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Atrial Fibrillation Pipeline Market

The key companies in the atrial fibrillation pipeline market are Correvio Pharma Corp, Daiichi Sankyo Co Ltd, Nissan Chemical Corp, Toa Eiyo Ltd, AbbVie Inc, Acesion Pharma Aps, and Aetas Pharma Co Ltd. Correvio Pharma Corp has the highest number of pipeline products.

Atrial Fibrillation Pipeline Market, by Companies

Atrial Fibrillation Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets Potassium Channel, Sodium Channel, Calcium Channel, Beta 1 Adrenergic Receptor, Coagulation Factor X, Coagulation Factor XI, and Muscarinic Gated Atrial Potassium Channel
Key MoA Potassium Channel Blocker, Sodium Channel Blocker, Calcium Channel Blocker, Beta 1 Adrenergic Receptor Antagonist, Coagulation Factor X Inhibitor, and Coagulation Factor XI Inhibitor
Key RoA Oral, Intravenous, Inhalational, Intracardiac, Intramuscular, Nasal, Parenteral, and Subcutaneous
Key molecule types Small Molecule, Gene Therapy, Protein, Monoclonal Antibody
Key companies Correvio Pharma Corp, Daiichi Sankyo Co Ltd, Nissan Chemical Corp, Toa Eiyo Ltd, AbbVie Inc, Acesion Pharma Aps, and Aetas Pharma Co Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

AbbVie Inc
Acesion Pharma Aps
Aetas Pharma Co Ltd
AnaBios Corp
Anthos Therapeutics Inc
ARCA biopharma Inc
Armaron Bio Pty Ltd
Bayer AG
Bristol-Myers Squibb Co
Chaperone Pharma BV
Chong Kun Dang Pharmaceutical Corp
Correvio Pharma Corp
Daiichi Sankyo Co Ltd
Espero BioPharma Inc
FB HRS LLC
G3 Pharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
HUYA Bioscience International LLC
Hyloris Pharmaceuticals SA
InCarda Therapeutics Inc
Inomagen Therapeutics Inc
Merck & Co Inc
Merz Pharma GmbH & Co KgaA
Milestone Pharmaceuticals Inc
Nissan Chemical Corp
Novartis AG
Rithim Biologics Inc
The Geneva Biotech Center SA
Toa Eiyo Ltd
Verseon Corp
Vivasc Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Atrial Fibrillation – Overview

Atrial Fibrillation – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Atrial Fibrillation – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Atrial Fibrillation – Companies Involved in Therapeutics Development

AbbVie Inc

Acesion Pharma Aps

Aetas Pharma Co Ltd

AnaBios Corp

Anthos Therapeutics Inc

ARCA biopharma Inc

Armaron Bio Pty Ltd

Bayer AG

Bristol-Myers Squibb Co

Chaperone Pharma BV

Chong Kun Dang Pharmaceutical Corp

Correvio Pharma Corp

Daiichi Sankyo Co Ltd

Espero BioPharma Inc

FB HRS LLC

G3 Pharmaceuticals Inc

Hanmi Pharmaceuticals Co Ltd

HUYA Bioscience International LLC

Hyloris Pharmaceuticals SA

InCarda Therapeutics Inc

Inomagen Therapeutics Inc

Merck & Co Inc

Merz Pharma GmbH & Co KgaA

Milestone Pharmaceuticals Inc

Nissan Chemical Corp

Novartis AG

Rithim Biologics Inc

The Geneva Biotech Center SA

Toa Eiyo Ltd

Verseon Corp

Vivasc Therapeutics Inc

Atrial Fibrillation – Drug Profiles

abelacimab – Drug Profile

Product Description

Mechanism Of Action

History of Events

amiodarone – Drug Profile

Product Description

Mechanism Of Action

History of Events

AP-30663 – Drug Profile

Product Description

Mechanism Of Action

History of Events

asundexian – Drug Profile

Product Description

Mechanism Of Action

History of Events

bucindolol hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

budiodarone – Drug Profile

Product Description

Mechanism Of Action

History of Events

CHAP-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CKD-825 – Drug Profile

Product Description

Mechanism Of Action

History of Events

danicamtiv – Drug Profile

Product Description

Mechanism Of Action

History of Events

dofetilide – Drug Profile

Product Description

Mechanism Of Action

edoxaban tosylate – Drug Profile

Product Description

Mechanism Of Action

History of Events

etripamil – Drug Profile

Product Description

Mechanism Of Action

History of Events

FBHRS-001 – Drug Profile

Product Description

Mechanism Of Action

flecainide acetate – Drug Profile

Product Description

Mechanism Of Action

History of Events

GBCA-1 – Drug Profile

Product Description

Mechanism Of Action

History of Events

gemibotulinumtoxin A – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy for Atrial Fibrillation – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy for Post-Operative Atrial Fibrillation – Drug Profile

Product Description

Mechanism Of Action

HBI-3000 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HIP-2001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HSY-244 – Drug Profile

Product Description

Mechanism Of Action

History of Events

incobotulinumtoxin A – Drug Profile

Product Description

Mechanism Of Action

History of Events

M-201 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MK-1832 – Drug Profile

Product Description

Mechanism Of Action

NIP-151 – Drug Profile

Product Description

Mechanism Of Action

NP-202 – Drug Profile

Product Description

Mechanism Of Action

History of Events

NTC-801 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Atrial Fibrillation – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Block GIRK for Atrial Fibrillation – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit LGALS3 for Cardiovascular and Genito Urinary System Disorders – Drug Profile

Product Description

Mechanism Of Action

TY-55348 – Drug Profile

Product Description

Mechanism Of Action

TY-55458 – Drug Profile

Product Description

Mechanism Of Action

VE-1902 – Drug Profile

Product Description

Mechanism Of Action

History of Events

vernakalant hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

Atrial Fibrillation – Dormant Projects

Atrial Fibrillation – Discontinued Products

Atrial Fibrillation – Product Development Milestones

Featured News & Press Releases

Dec 07, 2021: Atrial Fibrillation clinical trial with novel dual activity factor XI agent completes enrollment

Nov 15, 2021: Milestone Pharmaceuticals announces presentation of heart rate analysis of NODE-301 trial of Etripamil in Patients with PSVT

Nov 02, 2021: HUYABIO International announces initiation of phase 2 atrial fibrillation trial

Aug 30, 2021: ENVISAGE-TAVI AF data published in The NEJM demonstrates edoxaban’s noninferiority to VKAs in High-risk AF patients following successful heart valve procedure

Aug 28, 2021: New data support the use of LIXIANA (edoxaban) in complex patient populations with atrial fibrillation (AF)

Aug 28, 2021: Edoxaban may be effective treatment for atrial fibrillation after transcatheter aortic valve replacement

Jun 23, 2021: InCarda Therapeutics announces positive end-of-phase 2 meeting with FDA for InRhythm for Treatment of atrial fibrillation

Jun 09, 2021: InCarda Therapeutics provides corporate update highlighting new phase 2 data for InRhythm program, plans for pivotal phase 3 study and expansion of senior management team

Apr 26, 2021: New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA (edoxaban) in people with atrial fibrillation

Apr 21, 2021: Rhythm Therapeutics, awarded $3.67 Million NIH SBIR fast track grant to develop gene therapy for atrial fibrillation

Mar 29, 2021: Milestone Pharmaceuticals announces first patient enrolled in the ReVeRA study, its phase 2 trial of Etripamil in atrial fibrillation and rapid ventricular rate

Jan 19, 2021: InCarda Therapeutics announces enrollment of first U.S. patient in phase 2 INSTANT trial of InRhythm for treatment of atrial fibrillation

Nov 13, 2020: InCarda Therapeutics presents positive new data from phase 2 study of InRhythm in patients with paroxysmal atrial fibrillation at American Heart Association Scientific Sessions 2020

Sep 11, 2020: Daiichi Sankyo submits Supplemental Application in Japan for approval of partial changes in usage or dosage for Anticoagulant Edoxaban

Aug 31, 2020: New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and ageing AF patients on LIXIANA (edoxaban) during routine clinical care

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Atrial Fibrillation, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Atrial Fibrillation – Pipeline by AbbVie Inc, 2022

Atrial Fibrillation – Pipeline by Acesion Pharma Aps, 2022

Atrial Fibrillation – Pipeline by Aetas Pharma Co Ltd, 2022

Atrial Fibrillation – Pipeline by AnaBios Corp, 2022

Atrial Fibrillation – Pipeline by Anthos Therapeutics Inc, 2022

Atrial Fibrillation – Pipeline by ARCA biopharma Inc, 2022

Atrial Fibrillation – Pipeline by Armaron Bio Pty Ltd, 2022

Atrial Fibrillation – Pipeline by Bayer AG, 2022

Atrial Fibrillation – Pipeline by Bristol-Myers Squibb Co, 2022

Atrial Fibrillation – Pipeline by Chaperone Pharma BV, 2022

Atrial Fibrillation – Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022

Atrial Fibrillation – Pipeline by Correvio Pharma Corp, 2022

Atrial Fibrillation – Pipeline by Daiichi Sankyo Co Ltd, 2022

Atrial Fibrillation – Pipeline by Espero BioPharma Inc, 2022

Atrial Fibrillation – Pipeline by FB HRS LLC, 2022

Atrial Fibrillation – Pipeline by G3 Pharmaceuticals Inc, 2022

Atrial Fibrillation – Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022

Atrial Fibrillation – Pipeline by HUYA Bioscience International LLC, 2022

Atrial Fibrillation – Pipeline by Hyloris Pharmaceuticals SA, 2022

Atrial Fibrillation – Pipeline by InCarda Therapeutics Inc, 2022

Atrial Fibrillation – Pipeline by Inomagen Therapeutics Inc, 2022

Atrial Fibrillation – Pipeline by Merck & Co Inc, 2022

Atrial Fibrillation – Pipeline by Merz Pharma GmbH & Co KgaA, 2022

Atrial Fibrillation – Pipeline by Milestone Pharmaceuticals Inc, 2022

Atrial Fibrillation – Pipeline by Nissan Chemical Corp, 2022

Atrial Fibrillation – Pipeline by Novartis AG, 2022

Atrial Fibrillation – Pipeline by Rithim Biologics Inc, 2022

Atrial Fibrillation – Pipeline by The Geneva Biotech Center SA, 2022

Atrial Fibrillation – Pipeline by Toa Eiyo Ltd, 2022

Atrial Fibrillation – Pipeline by Verseon Corp, 2022

Atrial Fibrillation – Pipeline by Vivasc Therapeutics Inc, 2022

Atrial Fibrillation – Dormant Projects, 2022

Atrial Fibrillation – Dormant Projects, 2022 (Contd..1)

Atrial Fibrillation – Dormant Projects, 2022 (Contd..2)

Atrial Fibrillation – Discontinued Products, 2022

Atrial Fibrillation – Discontinued Products, 2022 (Contd..1)

Figures

List of Figures

Number of Products under Development for Atrial Fibrillation, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Atrial Fibrillation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Atrial Fibrillation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Atrial Fibrillation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.